Ensayos clínicos

8.676 ensayos encontrados

ReclutandoFase 3ClinicalTrials.gov

A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy, Pharmacokinetics and Safety of Remibrutinib (LOU064) for 24 Weeks in Adolescents From 12 to Less Than 18 Years of Age With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Followed by an Optional Open-label Extension for up to Another 3 Years and an Optional Safety Long-term Treatment-free Follow-up Period for up to an Additional 3 Years

INTERVENTIONALInicio: 11 de jul de 2023ID: NCT05677451

ReclutandoFase 4ClinicalTrials.gov

A Phase 4, Multicenter, Open-label, Single-arm Study to Investigate the Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate Atopic Dermatitis and High Itch Burden

INTERVENTIONALInicio: 16 de jun de 2025ID: NCT07006792

CompletadoFase 3ClinicalTrials.gov

Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease

INTERVENTIONALInicio: 17 de jun de 2019ID: NCT03819153

CompletadoFase 4ClinicalTrials.gov

A 24 Week Randomised, Open Label, 3 Parallel-group Comparison of Once and Twice Daily Biphasic Insulin Aspart (BIAsp) 30 Plus Sitagliptin and Twice Daily BIAsp 30, All in Combination With Metformin in Insulin naïve Type 2 Diabetic Subjects Inadequately Controlled on Sitagliptin and Metformin

INTERVENTIONALInicio: 1 de jun de 2012ID: NCT01519674

CompletadoFase 3ClinicalTrials.gov

A Trial Comparing Efficacy and Safety of NN1250 With Sitagliptin in Insulin Naive Subjects With Type 2 Diabetes (BEGIN™ : EARLY)

INTERVENTIONALInicio: 1 de ene de 2010ID: NCT01046110

TerminadoFase 3ClinicalTrials.gov

A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3

INTERVENTIONALInicio: 3 de sept de 2018ID: NCT03556202

CompletadoFase 3ClinicalTrials.gov

Effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects With Obesity-related Heart Failure With Preserved Ejection Fraction

INTERVENTIONALInicio: 16 de mar de 2021ID: NCT04788511

ReclutandoClinicalTrials.gov

Evaluation of Functional Recovery of Facial Paralysis in People With Different Kinesic Treatment Options.

INTERVENTIONALInicio: 1 de jun de 2023ID: NCT06532903

CompletadoFase 3ClinicalTrials.gov

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis

INTERVENTIONALInicio: 10 de mar de 2023ID: NCT05755438

ReclutandoFase 3ClinicalTrials.gov

A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

INTERVENTIONALInicio: 20 de jun de 2024ID: NCT06455449

CompletadoFase 4ClinicalTrials.gov

A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis

INTERVENTIONALInicio: 1 de jun de 2008ID: NCT00663052

CompletadoFase 3ClinicalTrials.gov

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of Remibrutinib (LOU064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (CSU) Patients Inadequately Controlled by H1-antihistamines

INTERVENTIONALInicio: 30 de nov de 2021ID: NCT05030311

Activo, no reclutaClinicalTrials.gov

A Prospective Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis

OBSERVATIONALInicio: 11 de jun de 2019ID: NCT03992417

CompletadoFase 4ClinicalTrials.gov

Linezolid in the Treatment of Subjects With Complicated Skin and Soft Tissue Infections Proven to be Due to Methicillin-Resistant Staphylococcus Aureus

INTERVENTIONALInicio: 1 de oct de 2004ID: NCT00087490

TerminadoFase 2ClinicalTrials.gov

A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC Injection in Adult Participants With Moderate to Severe Atopic Dermatitis

INTERVENTIONALInicio: 16 de nov de 2023ID: NCT05999799

CompletadoFase 3ClinicalTrials.gov

A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis

INTERVENTIONALInicio: 28 de mar de 2018ID: NCT03334435

TerminadoFase 2ClinicalTrials.gov

A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Phase 2b, 24 Week Trial Followed by an Open Label Extension of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

INTERVENTIONALInicio: 30 de oct de 2012ID: NCT01636843

TerminadoFase 3ClinicalTrials.gov

A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) vs Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities.

INTERVENTIONALInicio: 1 de jun de 2014ID: NCT02202135

CompletadoClinicalTrials.gov

Evaluation of the Efficacy and Tolerance of Two Cosmetic Products in Subjects Presenting With Rosacea Treated With Topical Treatment

INTERVENTIONALInicio: 16 de may de 2024ID: NCT06582043

Activo, no reclutaClinicalTrials.gov

Prospective, Observational, Longitudinal Study in Pediatric Patients With Moderate to Severe Atopic Dermatitis Whose Disease is Not Adequately Controlled With Topical Prescription Therapies or When Those Therapies Are Not Medically Advisable

OBSERVATIONALInicio: 15 de ago de 2019ID: NCT03687359